The next generation of therapies for adrenocortical cancers

Trends in Endocrinology and Metabolism

Volumn 23, Issue 7, 2012, Pages 343-350

  Kirschner, Lawrence S ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Adrenocortical carcinoma; Cytotoxic chemotherapy; Targeted chemotherapy; Tyrosine kinase inhibitors

Indexed keywords

BETA CATENIN; BEVACIZUMAB; BGJ 398; CAPECITABINE; CETUXIMAB; CISPLATIN; CIXUTUMUMAB; DOVITINIB; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FIGITUMUMAB; GEFITINIB; GEMCITABINE; INSULIN RECEPTOR; LAPATINIB; LINSITINIB; MESSENGER RNA; MITOTANE; PACLITAXEL; PIOGLITAZONE; PROTEIN TYROSINE KINASE INHIBITOR; ROSIGLITAZONE; SOMATOMEDIN B; SORAFENIB; STREPTOZOCIN; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT THERAPY; ADRENAL CORTEX CARCINOMA; ADRENALECTOMY; ADVANCED CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; COLON CANCER; CONTINUOUS INFUSION; FOLLOW UP; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LASER SURGERY; LUNG CANCER; MELANOMA; METASTASIS; MOLECULAR DIAGNOSIS; MYELOMA; NEUROTOXICITY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURGEON;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MITOTANE; TREATMENT OUTCOME;

EID: 84863106031     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2012.04.001     Document Type: Review

References (99)

1. Golden S.H., et al. Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J. Clin. Endocrinol. Metab. 2009, 94:1853-1878.
2. Crucitti F., et al. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 1996, 119:161-170.
3. Ng L., Libertino J.M. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J. Urol. 2003, 169:5-11.
4. Hahner S., Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr. Opin. Investig. Drugs 2005, 6:386-394.
5. Sullivan M., et al. Adrenal cortical carcinoma. J. Urol. 1978, 120:660-665.
6. Schteingart D.E., et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr. Relat. Cancer 2005, 12:667-680.
7. Porpiglia F., et al. A debate on laparoscopic versus open adrenalectomy for adrenocortical carcinoma. Horm. Cancer 2011, 2:372-377.
8. Berruti A., et al. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer 1998, 83:2194-2200.
9. Berruti A., et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr. Relat. Cancer 2005, 12:657-666.
10. Khan T.S., et al. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann. Oncol. 2000, 11:1281-1287.
11. Fassnacht M., et al. Etoposide, doxorubicin, cisplatin, and mitotane vs. streptozotocin and mitotane in adrenocortical carcinoma - (preliminary) results of the FIRM-ACT trial. Endocr. Rev. 2011, 32:P1-619.
12. Terzolo M., et al. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J. Clin. Endocrinol. Metab. 2000, 85:2234-2238.
13. Terzolo M., et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N. Engl. J. Med. 2007, 356:2372-2380.
14. Balasubramaniam S., Fojo T. Practical considerations in the evaluation and management of adrenocortical cancer. Semin. Oncol. 2010, 37:619-626.
15. Fassnacht M., et al. Adrenocortical carcinoma: a clinician's update. Nat. Rev. Endocrinol. 2011, 7:323-335.
16. Lacroix A. Approach to the patient with adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 2010, 95:4812-4822.
17. Polat B., et al. Radiotherapy in adrenocortical carcinoma. Cancer 2009, 115:2816-2823.
18. Sabolch A., et al. Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2011, 80:1477-1484.
19. Fassnacht M., et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 2006, 91:4501-4504.
20. Ripley R.T., et al. Liver resection and ablation for metastatic adrenocortical carcinoma. Ann. Surg. Oncol. 2011, 18:1972-1979.
21. Del Pizzo J.J. Radiofrequency ablation for adrenal lesions. Curr. Urol. Rep. 2006, 7:68.
22. Pacella C.M., et al. Percutaneous laser ablation of unresectable primary and metastatic adrenocortical carcinoma. Eur. J. Radiol. 2008, 66:88-94.
23. Gicquel C., et al. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab. 1994, 78:1444-1453.
24. Giordano T.J., et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am. J. Pathol. 2003, 162:521-531.
25. de Fraipont F., et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J. Clin. Endocrinol. Metab. 2005, 90:1819-1829.
26. Velazquez-Fernandez D., et al. Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery 2005, 138:1087-1094.
27. Slater E.P., et al. Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur. J. Endocrinol. 2006, 154:587-598.
28. de Reynies A., et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J. Clin. Oncol. 2009, 27:1108-1115.
29. Gaujoux S., et al. Beta-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin. Cancer Res. 2011, 17:328-336.
30. Durand J., et al. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations. J. Clin. Endocrinol. Metab. 2011, 96:E1206-E1211.
31. Patterson E.E., et al. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 2011, 117:1630-1639.
32. Ozata D.M., et al. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr. Relat. Cancer 2011, 18:643-655.
33. Tombol Z., et al. Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. Endocr. Relat. Cancer 2009, 16:895-906.
34. Rosenzweig S.A., Atreya H.S. Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem. Pharmacol. 2010, 80:1115-1124.
35. Barlaskar F.M., et al. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 2009, 94:204-212.
36. Haluska P., et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother. Pharmacol. 2010, 65:765-773.
37. Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 2009, 9:463-475.
38. Kamio T., et al. Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. Hum. Pathol. 1990, 21:277-282.
39. Sasano H., et al. Transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor expression in normal and diseased human adrenal cortex by immunohistochemistry and in situ hybridization. Mod. Pathol. 1994, 7:741-746.
40. Adam P., et al. Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. Mod. Pathol. 2010, 23:1596-1604.
41. Gutierrez C., Schiff R. HER2: biology, detection, and clinical implications. Arch. Pathol. Lab. Med. 2011, 135:55-62.
42. Shim H. One target, different effects: a comparison of distinct therapeutic antibodies against the same targets. Exp. Mol. Med. 2011, 43:539-549.
43. Samnotra V., et al. A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC). J. Clin. Oncol. 2007, 25:15527.
44. Quinkler M., et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J. Clin. Endocrinol. Metab. 2008, 93:2057-2062.
45. West A.N., et al. Gene expression profiling of childhood adrenocortical tumors. Cancer Res. 2007, 67:600-608.
46. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 2010, 10:116-129.
47. Xin X., et al. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin. Cancer Res. 2006, 12:4908-4915.
48. Loilome W., et al. Glioblastoma cell growth is suppressed by disruption of fibroblast growth factor pathway signaling. J. Neurooncol. 2009, 94:359-366.
49. Kim K.B., et al. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin. Cancer Res. 2011, 17:7451-7461.
50. Guagnano V., et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J. Med. Chem. 2011, 54:7066-7083.
51. Zhang H., et al. FP-1039 (FGFR1:Fc), a soluble FGFR1 receptor antagonist, inhibits tumor growth and angiogenesis. AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics Discovery, Biology and Clinical Applications 2007.
52. Tolcher A., et al. Preliminary results of a phase 1 study of FP-1039 (FGFR1:Fc), a novel antagonist of multiple fibroblast growth factor (FGF) ligands, in patients with advanced malignancies. Mol. Cancer Ther. 2009, 8:A103.
53. Zetter B.R. The scientific contributions of M. Judah Folkman to cancer research. Nat. Rev. Cancer 2008, 8:647-654.
54. Wortmann S., et al. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur. J. Endocrinol. 2010, 162:349-356.
55. Quinkler M., et al. Sunitinib in refractory adrenocortical carcinoma: results of a phase II trial. Endocr. Rev. 2011, 32:OR13-11.
56. van Erp N.P., et al. Mitotane has a strong and a durable inducing effect on CYP3A4 activity. Eur. J. Endocrinol. 2011, 164:621-626.
57. Butler C., et al. Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma. Endocr. Pract. 2010, 16:441-445.
58. Berruti A., et al. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur. J. Endocrinol. 2012, 166:451-458.
59. Memmott R.M., Dennis P.A. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell. Signal. 2009, 21:656-664.
60. Zhou H., et al. Updates of mTOR inhibitors. Anticancer Agents Med. Chem. 2010, 10:571-581.
61. Yuan R., et al. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J. Hematol. Oncol. 2009, 2:45.
62. Populo H., et al. The mTOR signalling pathway in human cancer. Int. J. Mol. Sci. 2012, 13:1886-1918.
63. Doghman M., et al. Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res. 2010, 70:4666-4675.
64. De Martino M.C., et al. Expression of mTOR pathway in human adrenocortical carcinomas and in vitro effects of mTOR inhibitors in human adrenocortical cell lines. Endocr. Abstracts 2009, 20:52.
65. Takahashi-Yanaga F., Sasaguri T. The Wnt/beta-catenin signaling pathway as a target in drug discovery. J. Pharmacol. Sci. 2007, 104:293-302.
66. Kim A.C., et al. Targeted disruption of beta-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex. Development 2008, 135:2593-2602.
67. Tadjine M., et al. Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clin. Endocrinol. (Oxf.) 2008, 68:264-270.
68. Gaujoux S., et al. Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. J. Clin. Endocrinol. Metab. 2008, 93:4135-4140.
69. Tissier F., et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 2005, 65:7622-7627.
70. Curtin J.C., Lorenzi M.V. Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget 2010, 1:563-577.
71. Cha J.Y., et al. Anti-tumor activity of novel small molecule Wnt signaling inhibitor, CWP232291, in multiple myeloma. 52nd American Society for Hematology Annual Meeting (Abstract 3038) 2010.
72. Doghman M., et al. The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. J. Clin. Endocrinol. Metab. 2008, 93:3222-3225.
73. Garber K. Drugging the Wnt pathway: problems and progress. J. Natl. Cancer Inst. 2009, 101:548-550.
74. Freedman A.N., et al. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J. Natl. Cancer Inst. 2010, 102:1698-1705.
75. Ronchi C.L., et al. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocr. Relat. Cancer 2009, 16:907-918.
76. Demeure M.J., et al. Targeted therapies for adrenocortical carcinoma: IGF and beyond. Horm. Cancer 2011, 2:385-392.
77. Blanquicett C., et al. Thiazolidinediones as anti-cancer agents. Cancer Ther. 2008, 6:25-34.
78. Betz M.J., et al. Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation. J. Clin. Endocrinol. Metab. 2005, 90:3886-3896.
79. Cantini G., et al. Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling. PPAR Res. 2008, 2008:904041.
80. Cerquetti L., et al. Rosiglitazone induces autophagy in H295R and cell cycle deregulation in SW13 adrenocortical cancer cells. Exp. Cell Res. 2011, 317:1397-1410.
81. Ferruzzi P., et al. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J. Clin. Endocrinol. Metab. 2005, 90:1332-1339.
82. Luconi M., et al. Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model. Endocr. Relat. Cancer 2010, 17:169-177.
83. Weng J.R., et al. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr. Relat. Cancer 2006, 13:401-413.
84. Schimmer B.P., White P.C. Minireview: steroidogenic factor 1: its roles in differentiation, development, and disease. Mol. Endocrinol. 2010, 24:1322-1337.
85. Sbiera S., et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J. Clin. Endocrinol. Metab. 2010, 95:E161-E171.
86. Doghman M., et al. Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists. J. Clin. Endocrinol. Metab. 2009, 94:2178-2183.
87. 123I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes. J. Clin. Endocrinol. Metab. 2008, 93:2358-2365.
88. 11C-metomidate PET imaging of adrenocortical cancer. Eur. J. Nucl. Med. Mol. Imaging 2003, 30:403-410.
89. 131I]Iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 2012, 97:914-922.
90. Sierra J.R., et al. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol. Cancer 2010, 9:75.
91. Jin Q., Esteva F.J. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J. Mammary Gland Biol. Neoplasia 2008, 13:485-498.
92. Jameson M.J., et al. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells. Mol. Cancer Ther. 2011, 10:2124-2134.
93. Huang F., et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res. 2009, 69:161-170.
94. min/+ mouse. Br. J. Cancer 2011, 105:649-657.
95. Naing A., et al. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin. Cancer Res. 2011, 17:6052-6060.
96. Kroiss M., et al. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin. Endocrinol. (Oxf.) 2011, 75:585-591.
97. Adrenal. AJCC Cancer Staging Manual (7th edn) 2010, 515-517. Springer. S.G. Edge (Ed.).
98. Fassnacht M., et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 2009, 115:243-250.
99. Lughezzani G., et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur. J. Cancer 2010, 46:713-719.